Reducing the "risk" of chemoprevention: Defining and targeting high risk - 2005 AACR Cancer Research and Prevention Foundation Award Lecture

被引:31
作者
Lippman, SM
Lee, JJ
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
D O I
10.1158/0008-5472.CAN-05-4573
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Two large-scale, phase III cancer prevention trials, the Breast Cancer Prevention Trial (BCPT) of tamoxifen and Prostate Cancer Prevention Trial (PCPT) of finasteride, concluded with strikingly positive and simultaneously problematic results: reduced cancer risks but a major adverse finding with each agent that prevented its widespread use in the community. For most moderate-risk people, such as those studied in the BCPT and PCPT, the benefit of reduced breast or prostate cancer does not outweigh the major risk of tamoxifen (endometrial cancer in the BCPT) or apparent risk of finasteride (high-grade prostate cancer in the PCPT). Promising interventions with biologically active substances are likely to have adverse, perhaps unforeseen effects, especially with long-term preventive use. Acceptance of such agents will depend heavily on the level of cancer risk of the target population. This article outlines research in molecularly identified high-risk oral intraepithelial neoplasia that creates the clinical opportunity for optimizing the risk-benefit ratio of agents to prevent oral cancer. Two other major research efforts focused on improving preventive agent risk-benefit ratios are molecular-targeted research designed to target away from known adverse signaling pathways and multidisciplinary research based on the PCPT that will develop comprehensive models of prostate cancer risk (especially of aggressive prostate cancer) and pharmacoecogenetic models for identifying high-risk men most likely to benefit from (and not be harmed by) finasteride or similar (5 alpha-reductase inhibiting) agents. Defining and targeting high-risk populations, developing molecular-targeted approaches, and developing accurate pharmacoecogenetic models promise to reduce the risk of chemoprevention and ultimately to reduce the risk and burden of major cancers.
引用
收藏
页码:2893 / 2903
页数:11
相关论文
共 137 条
[1]   The convergence of cancer prevention and therapy in early-phase clinical drug development [J].
Abbruzzese, JL ;
Lippman, SM .
CANCER CELL, 2004, 6 (04) :321-326
[2]  
Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
[3]   Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer [J].
Altorki, NK ;
Keresztes, RS ;
Port, JL ;
Libby, MD ;
Korst, RJ ;
Flieder, DB ;
Ferrara, CA ;
Yankelevitz, DF ;
Subbaramaiah, K ;
Pasmantier, MW ;
Dannenberg, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2645-2650
[4]   Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line [J].
Arico, S ;
Pattingre, S ;
Bauvy, C ;
Gane, P ;
Barbat, A ;
Codogno, P ;
Ogier-Denis, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (31) :27613-27621
[5]  
Averbuch SD, 2002, CLIN CANCER RES, V8, P1
[6]   15-hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer [J].
Backlund, MG ;
Mann, JR ;
Holla, VR ;
Buchanan, FG ;
Tai, HH ;
Musiek, ES ;
Milne, GL ;
Katkuri, S ;
DuBois, RN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (05) :3217-3223
[7]  
Bedi GC, 1996, CANCER RES, V56, P2484
[8]   Transforming growth factor-α:: A surrogate endpoint biomarker? [J].
Beenken, SW ;
Hockett, R ;
Grizzle, W ;
Weiss, HL ;
Pickens, A ;
Perloff, M ;
Malone, WF ;
Bland, KI .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2002, 195 (02) :149-158
[9]   PREVENTION OF 2ND PRIMARY TUMORS WITH ISOTRETINOIN IN PATIENTS WITH SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - LONG-TERM FOLLOW-UP [J].
BENNER, SE ;
PAJAK, TF ;
LIPPMAN, SM ;
EARLEY, C ;
HONG, WK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (02) :140-141
[10]  
BONNER JA, 1996, NEW ENGL J MED, V354, P567